Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
מצבים רפואיים
Inflammatory Bowel Disease (IBD) · Crohn Disease (CD) · Ulcerative Colitis (UC) · IBD-unclassified (IBD-U)
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
University of Calgary, Calgary, Alberta, Canada
Contact: Principal Investigator (Joëlle St-Pierre, MD)MA MacMillan, Fredericton, New Brunswick, Canada
Contact: Principal Investigator (Mark MacMilan, MD, FRCPC, CAGF)Hamilton Health Sciences Corporation, Hamilton, Ontaio, Canada
Contact: Principal Investigator (Neeraj Narula, MD)Barrie GI Associates, Barrie, Ontario, Canada
Contact: Study coordinator (Colayna Harris-Mailloux, RN, BScN) · researchclinic@barriegi.ca · 705-721-3344Contact: Principal Investigator (Lindsay Crabbe, MD)Brampton Gastroenterology Research Group Inc, Brampton, Ontario, Canada
Contact: Principal Investigator (Andrew Bellini, MD)GNRR Digestive Clinics and Research Center Inc., Brampton, Ontario, Canada
Contact: Principal Investigator (Girish Bajaj, MD)LDDI Clinical Trials Inc. dba London Digestive Disease Institute, London, Ontario, Canada
Contact: Principal Investigator (Vipul Jairath, MD)West Gta Research Inc., Mississauga, Ontario, Canada
Contact: Principal Investigator (Callum Dargavel, MD)Abp Research Services Corporation, Oakville, Ontario, Canada
Contact: Principal Investigator (Naveen Arya, MD)Taunton Surgical Center, Oshawa, Ontario, Canada
Contact: Principal Investigator (Daniel Green, MD)Toronto Immune and Digestive Health Institute, Toronto, Ontario, Canada
Contact: Principal Investigator (Petros Zesos, MD)The Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
Contact: Principal Investigator (Waqqas Afif, MD)
מובילי המחקר
Laura E. Targownik, MD, MSHS, FRCPC
Principal Investigator
TIDHI Innovation Inc.
Mark Silverberg, MD, PhD, FRCPC
Principal Investigator
TIDHI Innovation Inc.